Historical landmarks in the understanding of the lymphomas

Neoplastic Diseases of the Blood

Volumn , Issue , 2013, Pages 789-833

  Lichtman, Marshall A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Lymph nodes; Lymphoma; Radiotherapy

Indexed keywords

EID: 84929570734     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3764-2_39     Document Type: Chapter

References (180)

1. Nerlich AG, Rohrbach H, Bachmeier B, Zink A. Malignant tumors in two ancient populations: an approach to historical tumor epidemiology. Oncol Rep. 2006;16:197-202.
2. Pahl WM. Tumors of bone and soft tissues in ancient Egypt and Nubia: synopsis of detected cases. Int J Anthropol. 1986;1:267-76.
3. Halperin EC. Paleo-oncology: The role of ancient remains in the study of cancer. Perspect Biol Med. 2004;47:1-14.
4. Wiesen SJ. German industry and the Third Reich. Dimensions. 1999;13:1-9.
5. Adelman HB. Marcello Malpigi and the evolution of embryology, vol. I. Ithaca, NY: Cornell University Press; 1960. p. 456-61.
6. Virchow R. Cellular pathology as based upon physiological and pathological histology. Translated by Frank Chance from the second German edition published in 1863. New York: Dover Publications; 1971. p. 189-210.
7. Huard P, Imbault-Huart MJ, Peyer JC. Complete dictionary of medical biography. New York: Charles Scribner's Sons; 2008. Encyclopedia.com.
8. Gaylord HR, Aschoff L. The principles of pathological histology. Chap X. In: The lymph nodes. Philadelphia and New York: Lea Brothers & Co; 1901. p. 189-94.
9. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans. 1832;17:68-114.
10. Murray TJ. Robert Carswell: thefirst illustrator of MS. Int MS J. 2009;16:98-101.
11. Hollman A. The paintings and pathological anatomy by Sir Robert Carswell (1793-1857). Heart. 1995;74:566-70.
12. Carswell R. Pathological anatomy: illustrations of the elementary forms of disease. London, UK: Longman; 1838.
13. Dawson P. The original illustrations of Hodgkin's disease. Ann Diagn Pathol. 1999;3:386-9.
14. Craige D. Elements of general and pathological anatomy. Edinburgh: Adam Black; 1828. p. 250.
15. Kaplan H. Hodgkin disease, Historical aspects. 2nd ed. Cambridge, MA: Harvard University Press; 1980. p. 2-15. Chap 1.
16. Thompson Hancock PE. Thomas Hodgkin. The Fitzpatrick Lecture. J R Coll Phys. 1966;2:404-21.
17. Hancock BW. Early clinical pathologists. 2. Thomas Hodgkin:pathologist, physician, and philanthropist. J Clin Pathol. 1990;43:616-8.
18. Bonadonna G. Historical review of Hodgkin's disease. Br J Haematol. 2000;110:504-11.
19. Sakula A. Dr Thomas Hodgkin and Sir Moses Montefiore Bart-The friendship of two remarkable men. J R Soc Med. 1979;72:382-7.
20. Notes and queries. Yet another note on the tombstone of Thomas Hodgkin. J Hist Med. 1954;IX:247-8.
21. Wilks S. Cases of lardaceous disease and some allied affections, with remarks. Guys Hosp Rep. 1856;17:103-32.
22. Wilks S. Cases with enlargement of the lymphatic glands and spleen (or Hodgkin's disease), with remarks. Guys Hosp Rep. 1865;11:56-67.
23. Fox H. Remarks on the presentation of microscopical preparations made from some of the original tissue described by Thomas Hodgkin, 1832. Ann Med Hist. 1926;8:370-4.
24. Poston RN. Positive Leu-MI immunohistochemistry and diagnosis of the lymphoma cases described by Hodgkin in 1832. Appl Immunohistochem Mol Morphol. 1999;7:6-8.
25. Strum SB. The natural history, histopathology, staging, and mode of spread of Hodgkin's disease. Ser Haematol. 1973;6:20-115.
26. Greenfield WS. Specimens illustrative of the pathology of lymphadenoma and leucocythemia. Trans Path Soc Lond. 1878;XXIX: 272-304.
27. Wilks S. IX. Special communications. (A) On diseases of the lymphatic system, including lymphadenoma and leukaemia. Trans Path Soc Lond. 1878;29:269-72.
28. Langerhans T. Das milgne lymphosarkom (pseudoleukämie). Virchows Arch Pathol Anat. 1872;54:509-37.
29. Dreschfeld J. Clinical lecture on acute Hodgkin's (or pseudoleucocythemia). BMJ. 1892;1:893-6.
30. Sternberg C. Uber eine eigenartige unter dem Bilde der Psuedoleukamie verlaufende Tuberculose des lymphatische Apparates. Ztschr Heilk. 1898;19:21-90.
31. Reed DM. On the pathological changes in Hodgkin's disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902;10:133-96.
32. Jackson H, Parker Jr F. Hodgkin's disease II. Pathology. N Engl J Med. 1944;231:35-44.
33. Peters M. A study of survivals in Hodgkin's disease treated radiologically. Am J Roentgenol. 1950;63:299-311.
34. Kinmonth J. Lymphangiography in man: method of outlining lymphatic trunks and operation. Clin Sci. 1952;11:13-20.
35. Lukes RJ, Butler JJ, Hicks EB. Natural history of Hodgkin's disease as related to its pathologic picture. Cancer. 1966;19:317-44.
36. Lukes RJ, Craver LF, Hall TC, Rappaport H, Rubin P. Report of the nomenclature committee. Cancer Res. 1966;26:1311.
37. Rosenberg S. Report of the committee on the staging of Hodgkin's disease. Cancer Res. 1966;26:1310.
38. Glatstein E, Guernsey JM, Rosenberg SA, et al. The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer. 1969;24:709-18.
39. Carbone P, Kaplan H, Musshoff K. Report of the committee on the Hodgkin's disease staging. Cancer Res. 1971;31:1860-1.
40. Weiss LM, Strickler JG, Warnke RA, et al. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol. 1987;129: 86-91.
41. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med. 1989;320:502-6.
42. Küppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A. 1994;91:10962-6.
43. Küppers R, Kanzler H, Hansmann ML, Rajewsky K. Single cell analysis of Hodgkin/Reed-Sternberg cells. Ann Oncol. 1996;7 Suppl 4:27-30.
44. Jox A, Zander T, Kornacker M, et al. Detection of identical Hodgkin-Reed Sternberg cell specific immunoglobulin gene rearrangements in a patient with Hodgkin's disease of mixed cellularity subtype at primary diagnosis and in relapse two and a half years later. Ann Oncol. 1998;9:283-7.
45. Pel P. Zur Symptomatologie der sogenannten Pseudo-Leukãmie. Berl klin Wochenschrift. 1885;22:3-7.
46. Brockbank EM, editor. Dreschfeld memorial volume: containing an account of the life, work, and writings of Julius Dreschfeld, M.D. F.R.C.P. with a series of original articles dedicated to his memory by his colleagues in the University of Manchester and former pupils. Manchester: University Press; 1908. University of Manchester Publication Number XXXV.
47. Ewing J. Neoplastic diseases: A textbook on tumors. Hodgkin granuloma. Lymphogranuloma. Philadelphia PA: WB Saunders Company; 1919. p. 352-61.
48. Stein H. Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008. p. 322-34.
49. Warren R. Kinmonth, MS, FRCS. Arch Surg. 1963;118:990-1.
50. Brousset P, Chittal S, Schlaifer D, et al. Detection of Epstein-Barr virus messenger RNA in Reed-Sternberg cells of Hodgkin's disease by in situ hybridization with biotinylated probes on specially processed modified acetone methyl benzoate xylene (ModAMeX) sections. Blood. 1991;77:1781-6.
51. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9:15-27.
52. Pusey WA. Cases of sarcoma and Hodgkin's disease treated by exposure to X-rays-A preliminary report. JAMA. 1902;38: 166-96.
53. Senn N. Therapeutical value of the Röntgen ray in treatment of pseudoleukemia. NY Med J. 1903;77:665-8.
54. Kaplan H. Hodgkin disease, Radiotherapy. 2nd ed. Cambridge, MA: Harvard University Press; 1980. p. 2-15. Chap 9.
55. Gilbert R, Babaïaintz L. Notre méthod de roentgenthérapie de la lymphogranulomatose (Hodgkin): résultats, éloignés. Acta Radiol. 1931;12:523-9.
56. Gilbert R. Radiotherapy in Hodgkin's disease (malignant granulomatosis): anatomic and clinical foundations; governing principles; results. Am J Roentgenol. 1939;41:198-241.
57. Craft CB. Results with roentgen ray therapy in Hodgkin's disease. Bull Staff Meet Univ Minnesota Hosp. 1940;11:391-409.
58. Cowen DH. Vera Peters and the curability of Hodgkin's disease. Curr Oncol. 2008;15:206-10.
59. Easson EC, Russell MH. The cure of Hodgkin's disease. Brit Med J. 1963;1:1704-7.
60. Goodman LS, Wintrobe MM, Dameshek W, et al. Use of methylbis( beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl) amine hydrochloride for Hodgkin's disease lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA. 1946;132:126-32.
61. Jacobsen L, Spurr CL, Barron ESG, et al. Nitrogen mustard therapy. Studies on the effect of methyl-bis (beta-chloroethyl) amine hydrochloride on neoplastic diseases and allied disorders of the hemopoietic system. JAMA. 1946;132:263-71.
62. Wilkinson JF, Fletcher J. Effects of B-chlorethylamine hydrochlorides in leukemia, Hodgkin's disease, and polycythemia vera. Lancet. 1946;i:540-5.
63. Kaplan HS. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res. 1996;26((part1)): 1221-4.
64. Kaplan HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology. 1962;78:553-61.
65. Devita Jr VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73:881-95.
66. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252.
67. Ribatti D. The contribution of Gianni Bonadonna to the history of chemotherapy. Cancer Chemother Pharmacol. 2007;60:309-12.
68. Spitzer G, Dicke K, Zander AR, et al. High-dose chemotherapy with autologous boner marrow transplantation. Cancer. 1984;54: 1216-25.
69. Appelbaum FR, Sullivan KM, Thomas ED, et al. Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. J Clin Oncol. 1985;3:1490-4.
70. Diehl V, Sieber M, Rüffer U, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol. 1997;8:143-8.
71. Glatstein E. As good as it gets-training with Henry Kaplaan and Saul Rosenberg during Stanford studies on Hodgkin's disease and lymphoma. Cancer Biother Rad. 2001;16:269-73.
72. Rosenberg S, Kaplan HS. Evidence for an orderly progression in the spread of Hodgkin's disease. Cancer Res. 1966;26((part 1)): 1225-31.
73. Krumbar EB, Krumbar HD. The blood and bone marrow in yellow cross (mustard) gas poisoning: changes produced in the marrow of fatal cases. J Med Res. 1919;40:487-508.
74. Adair FE, Bagg HJ. Experimental and clinical studies on the treatment of cancer by dichloroethylsulfide (mustard gas). Ann Surg. 1931;93:190-9.
75. Liebow AA, Waters LL. Milton Charles Winternitz. Yale J Biol Med. 1959;32:143-65.
76. Infield GB. Disaster at Bari. New York: The Macmillian Co; 1971. p. 1-251.
77. Gilman A, Philips FS. The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science. 1946;103:409-15.
78. Kohn KW. Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment-fifteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1996;56:5533-46.
79. Bollag W, Gruneberg E. Tumor inhibitory effects of a new class of cytotoxic agents; methyl ydrazine derivatives. Experientia. 1963;19:130-1.
80. Pearson OH, Eliel LP. Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias. JAMA. 1950;144:1349-53.
81. Noble RL, Beer CT, Cutis JH. Role of chance observations in chemotherapy: Vinca rosea. Ann N Y Acad Sci. 1958;76:882-94.
82. DeVita Jr VT. A selective history of the therapy of Hodgkin's disease. Br J Haematol. 2003;122:718-27.
83. Arseneau JC, Sponzo RW, Levin DL, et al. Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med. 1972;287:1119-22.
84. DeVita VT, Arseneau JC, Sherins RJ, et al. Intensive chemotherapy for Hodgkin's disease: long-term complications. Natl Cancer Inst Monogr. 1973;36:447-54.
85. Rutledge RH. A medical musical friendship: Billroth and Brahms. J Surg Educ. 2007;64(1):57-60.
86. Billroth T, von Winiwarter A. Die allgemeine chirurgische Pathologie und Therapie in einundfunfzig Vorlesungen: Ein Handbuch fur Studirende und Aerzte. Berlin: Druck und Verlag von George Reimer; 1893.
87. von Theodor Billroth. Neue Beobachtungen über die feinere structur pathologisch veranderter lymphdrüsen. Virchows Arch Pathol Anat Physiol Klin Med. 1861;21:423-43.
88. Kundrat H. Ueber lympho-sarkomatosis. Wien klin Wschr. 1893;VI:211-3, and 234-239.
89. Virchow R. Die Krankhaften Geschwulste, vol. 2. Berlin: Hirschwald; 1863. p. 728-38 (756 pages).
90. Mallory FB. The principles of pathologic histology. Philadelphia and London: W.B. Saunders Company;1914. Tumors, 8. Lymphoblastoma, pp 326-34.
91. http://www.fundinguniverse.com/company-histories/ MemorialSloan-Kettering-Cancer-Center .
92. Oberling C. Les reticulosarcomes et les reticuloendotheliosarcomes de la moelle osseuse (sarcmes d'Ewing). Bull Ass Franç Cancer. 1928;17:259-96.
93. Roulet F. Das primare Retothelsarcom der lymphknoten. Virch Arch Pathol Anat. 1930;277:15-47.
94. Brill NE, Baehr G, Rosenthal N. Generalized giant lymph follicle hyperplasia of lymph nodes and spleen. JAMA. 1925;84:668-71.
95. Symmers D. Giant follicular lymphadenopathy with or without splenomegaly. Arch Pathol. 1938;26:603-47.
96. Callender GR. Tumors and tumor-like conditions of the lymphocyte, the myelocyte, the erythrocyte, and the reticulum cell. Am J Pathol. 1934;X:443-65.
97. Gall EA, Mallory TB. Malignant lymphoma: A clinicopathologic survey of 618 cases. Am J Pathol. 1942;18:381-429.
98. Rappaport H, Winter W, Hicks E. Follicular lymphoma: A re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer. 1956;9:792-821.
99. Rappaport H. Tumors of the hematopoietic system, Fasc 8. Washington, DC: Armed Forces Institute of Pathology; 1966.
100. Gerard-Marchant R, Hamlin I, Lennert K, et al. Classification of non-Hodgkin's lymphoma. Lancet. 1974;ii:406-8.
101. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer. 1974;34 Suppl 4:1488-503.
102. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-35.
103. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292-3.
104. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84:361-92.
105. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haemoatpoietic and lymphoid tissues. Lyon: IARC Press; 2008.
106. Glick B, Chang TS, Jaap RG. The bursa of Fabricius and antibody production. Poult Sci. 1956;35:224-5.
107. Warner NL, Szenberg A. Effect of neonatal thymectomy on the immune response in the chicken. Nature. 1962;196:784-5.
108. Cooper MD, Peterson RD, South MA, Good RA. The functions of the thymus and the bursa system in the chicken. J Exp Med. 1966;123:75-102.
109. Miller JFAP. Immunologic function of the thymus. Lancet. 1961;2:748-9.
110. Roitt IM, Greaves MF, Torrigiani G, et al. The cellular basis of the immunological response. Lancet. 1969;2:367-71.
111. Coombs RRA, Gurner BW, Wilson AB, et al. Rosette formation between human lymphocytes and sheep red cells not involving immunoglobulin receptors. Int Arch Allerg Appl Immunol. 1970;39:658-63.
112. Coombs RRA, Feinstein A, Wilson AB. Immunoglobulin determinants on the surface of human lymphocytes. Lancet. 1969;ii: 1157-60.
113. Wilson JD, Nossal GJV. Identification of human T and B lymphocytes in normal peripheral blood and in chronic lymphocytic leukaemia. Lancet. 1971;ii:788-91.
114. Jondal M, Holm G, Wigzell H. Surface markers on human T and B lymphocytes. J Exp Med. 1972;136:207-15.
115. Klein E, Klein G, Nadkarni JS, et al. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 1968;28:1300-10.
116. Preud'homme JL, Klein M, Veroust P, Seligmann M. Immunoglobulines monoclonales de membrane dans les leucémies lymphoides chroniques. Rev Eur Étud Clin et Biol. 1971;16:1025-31.
117. Sinkovics JG, Shirato E, Martin RG, Cabiness JR, White EC. Chondrosarcoma. Immune reactions of a patient to autologous tumor. Cancer. 1971;27:782-93.
118. Sinkovics JG. Cytolytic immune lymphocytes. Passau: Schenk Verlag; 2008. p. 1-383.
119. Sinkovics JG. Malignant lymphoma arising from natural killer cells; Report of thefirst case in 1970 and newer developments in the FASL-FASR system. Acta Micrbiol Immunol Hung. 1997;44:295-307.
120. Herberman RB, Ortaldo JR. Natural killer cells: their roles in defenses against disease. Science. 1981;214:24-30.
121. Arnold A, Cossman J, Bakhshi A, et al. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med. 1983;309:1593-9.
122. Aisenberg AC, Krontiris TG, Mak TW, Wilkes BM. Rearrangement of the gene for the beta chain of the T-cell receptor in T-cell chronic lymphocytic leukemia and related disorders. N Engl J Med. 1985;313:529-33.
123. Stein H, Kaiserling E, Lennert K. Evidence for B-cell origin of reticulum cell sarcoma. Virchows Arch A Pathol Anat Histol. 1974;364:51-67.
124. Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-18.
125. Fulwyler MT, Glascock RB, Hiebert RD, Johnson NM. Device which separates minute particles according to electronically sensed volume. Rev Sci Instrum. 1969;40:42-8.
126. Cram LS, Arndt-Jovin D. Mack Jett Fulwyler, pioneer offlow cytometry andflow sorting (1936-2001). Cytometry A. 2005;67: 53-60.
127. Bonner WA, Hulett HR, Sweet RG, Herzenberg LA. Fluorescence activated cell sorting. Rev Sci Instrum. 1972;43:404-9.
128. Herzenberg LA, Parks DE, Sahaf B, et al. The historyand future offluorescence activated cell sorter andflow cytometry; a view from Stanford. Clin Chem. 2002;48:1819-27.
129. Staudt LM, Brown PO. Genomic views of the immune system. Ann Rev Immunol. 2000;18:829-59.
130. Alizadeh AA, Eisen MB, Davis RE, et al. Identification of molecularly and clinically distinct types diffuse large B-cell lymphoma by gene expression profiling. Nature. 2000;403:503-11.
131. Lenoir T, Giannella E. The emergence and diffusion of DNA microarray technology. J Biomed Discov Collab. 2006;1:11-29.
132. Geiges M, Kempf W, Burg G. Cutaneous lymphoma-historical aspects. In: Burg G, Kempf W, editors. Cutaneous lymphomas. Boca Raton: Taylor & Francis; 2005. p. 1-6.
133. Fraser JF. Mycosis fungoides: its relation to leukemia and lymphosarcoma. Arch Dermatol Syphilol. 1925;12:814-28.
134. Sézary A, Bouvrain Y. Erythrodermie avec présence de cellules monstrouse dans le derme et le sang circulant. Bull Soc Franç Derm Syph. 1938;45:254-60.
135. Brouet J-C, Flandrin G, Seligmann M. Indication of the thymusderived nature of the proliferating cells in six patients with Sézary syndrome. N Engl J Med. 1973;289:341-4.
136. Lutzner M, Edelson R, Schein P, Green I, Kirkpatrick C, Ahmed A. Cutaneous T-cell lymphomas: Sézary syndrome, mycosis fungoides, and related disorders. Ann Inter Med. 1975;83:534-52.
137. Schein PS, Chabner BA, Canellos GP, et al. Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma. Blood. 1974;43:181-9.
138. Forero A, LoBuglio AF. History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol. 2003;30:1-5.
139. Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. 1984;81: 6851-5.
140. Reff ME, Braslawsky G. Future of monoclonal antibodies in the treatment of hematological malignancies. Cancer Control. 2002;9:152-66.
141. Reff ME. The discovery of rituxan. In: Smith CT, O'Donnell JT, editors. New drug discovery and development. 2nd ed. New York, NY: Informa Healthcare; 2006. p. 565-84.
142. Burkitt DP. A sarcoma involving the jaws in African children. Br J Surg. 1958;46:218-23.
143. O'Conor GT, Davies JNP. Malignant tumors in African children. With special reference to malignant lymphoma. J Pediatr. 1960;56:526-35.
144. Tselis A. The history of Epstein-Barr virus. In: Tselis A, Jenson HB, editors. Epstein-Barr virus. New York: Taylor & Francis; 2006. p. 1-19.
145. Burkitt D. A lymphoma syndrome in African children. Lecture delivered at the Royal College of Surgeons of England on May 24th, 1961. Ann R Coll Surg Engl. 1962;30:211-9.
146. Epstein MA, Achong BG. Barr. Virus particles in cultured lymphoblast from Burkitt's lymphoma. Lancet. 1964;1:702-3.
147. Story JA, Kritchevsky D. Denis Parsons Burkitt (1911-1993). J Nutr. 1994;124:1551-4.
148. Manolov G, Manòlova Y. Marker band on one chromosome 14 from Burkitt lymphoma. Nature. 1972;237:33-4.
149. Zech L, Haglund V, Nilsson K, Klein G. Characteristic chromosome abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer. 1976;17:47-56.
150. Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A. 1982;79:7837-41.
151. Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79:7824-7.
152. Bernheim A, Berger R, Lenoir G. Cytogenetic studies on African Burkitt's lymphoma cell lines t(8;14), t(2;8) and t(8;22) translocations. Cancer Genet Cytogenet. 1981;3:307-15.
153. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097-9.
154. Hockenbery D, Nuñez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348:334-6.
155. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A. 1991;88:9638-42.
156. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med. 1994;331:74-80.
157. Reis MD, Griesser H, Mak TW. T cell receptor and immunoglobulin gene rearrangements in lymphoproliferative disorders. Adv Cancer Res. 1989;52:45-80.
158. Oettgen HF, Burkitt D, Burchenal JH. Malignant lymphoma involving the jaw in African children: treatment with methotrexate. Cancer. 1963;16:616-23.
159. Burkitt D. Long-term remissions following one and two dose chemotherapy for African lymphoma. Cancer. 1967;20:756-9.
160. Li MC, Hertz R, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med. 1956;93:361-6.
161. Gallo RC. History of the discoveries of thefirst human retroviruses; HTLV-1 and HTLV-2. Oncogene. 2005;24:5926-30.
162. Mier JW, Gallo RC. Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned medium. Proc Natl Acad Sci U S A. 1980;77:6134-8.
163. Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T cell lymphoma. Proc Natl Acad Sci U S A. 1980;77:7415-9.
164. Uchiyama T, Yodoi J, Sagawa K, Takatusi K, Uchino H. Adult T cell leukemia. Clinical and hematologic features of 16 cases. Blood. 1977;50:481-92.
165. Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A. 1981;78:6476-80.
166. Seiki M, Hattori S, Yoshida M. Human adult T-cell leukemia virus: molecular cloning of the provirus DNA and the unique terminal structure. Proc Natl Acad Sci U S A. 1982;79:6899-902.
167. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982;79: 2030-5.
168. Yoshida M. Discovery of HTLV-1, thefirst human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene. 2005;24:5931-7.
169. Boveri T. Concerning the origin of malignant tumours. J Cell Sci. 2008;121 Suppl 1:1-84.
170. Rous P. Transmission of a malignant new growth by means of a cell-freefiltrate. JAMA. 1911;56:198.
171. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Nat Can Inst. 1981;66:1191-308.
172. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;i:1273-5.
173. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;i:1311-5.
174. Freedberg AS, Baron LE. The presence of spirochetes in the gastric mucosa. Am J Dig Dis. 1940;7:443-5.
175. Steer HW, Colin-Jones DG. Mucosal changes in gastric ulceration and their response to carbenoxolone sodium. Gut. 1975;16:590-7.
176. Parsonnet J, Friedman ED, Vandersteen DP, Chang Y, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127-31.
177. Wyatt JI, Rathbone BJ. Immune response of the gastric mucosa to Campylobacter pylori . Scand J Gastroenterol. 1988;23:44-9.
178. Stolt M, Eidt S. Lymphoid follicles in the antral mucosa: immune response to Campylobacter pylori . J Clin Pathol. 1989;42: 1269-71.
179. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori . Lancet. 1993;342:575-7.
180. Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer. 1983;53: 2512-24.